Arvind Raghavan Email & Phone Number

Bedford, MA, US

Durham, North Carolina, US

Developing global regulatory strategies and enabling the achievement of regulatory milestones in vaccine development at a major pharma company.

Newton, Massachusetts, US

Delivered regulatory, product development and global compliance solutions for clients developing and marketing drugs, biologics, and medical devices.

Plymouth, Minnesota, US

Developed and incorporated evidence-based approaches into a digital platform created to improve health outcomes in breast cancer survivors.

Directed molecular and cell biology R&D to validate a nanotechnology platform for nuclear delivery of therapeutics.

Managed the testing & preclinical development of novel drug candidates for epilepsy and neuropathic pain.

Helped transition a startup from concept to preclinical development of a bispecific T-cell engager (BiTE) for breast & prostate cancer.

Minneapolis, MN, US

Managed preclinical development of the company’s lead biologic for new therapeutic indications in renal and metabolic disease.

Liaised with executive leadership and performed due diligence on IP, competitive landscape and market opportunities to support creation of a University spin-off biotechnology company. Project management of seed-stage grant to University startup to ensure technical milestones and deliverables were met.

Princeton, New Jersey, US

Established and managed strategic alliances with major pharmaceutical companies for the preclinical development of novel therapeutics for neurodegenerative and inflammatory diseases. - Supervised and led scientific staff in screening and lead optimization of drugs for neurodegenerative and inflammatory diseases.- Interacted directly with and supported.

Minneapolis, MN, US

Investigated effects of novel therapeutics on gene expression in liver cell regeneration & liver cancers.

Rochester, Minnesota, US

Awarded $50K post-doctoral fellowship from Susan G. Komen Breast Cancer Foundation to investigate the role of novel tumor suppressors in breast and ovarian cancer.Designed and executed retrovirus-based siRNA knock-down of tumor suppressor genes to generate chemotherapeutic-resistant breast cancer cell lines.

Minneapolis And St. Paul, Minnesota, US

- Designed, implemented and published studies on gene expression profiling of activated, malignant, and HIV-infected T-cells, using microarray technology.- Established collaborative research projects to profile gene expression responses during viral infection and CD8+ T-cell development.- Developed strategy & methodology for bioinformatic analysis of novel.

- Drafted & implemented cGLP & cGMP protocols to ensure FDA-compliance.- Contributed to the preparation of Abbreviated New Drug Applications (ANDAs).- Audited & supervised scientists involved in Active Pharmaceutical Ingredient (API) Quality Control & Quality Assurance.

Master Of Science - Ms, Regulatory Affairs

Doctor Of Philosophy (Ph.D.), Molecular Biology

Master Of Science (M.Sc.), Life Sciences